Xcout IntelEliksa Therapeutics
Eliksa Therapeutics, Inc. is a venture-backed biotechnology company based in Doylestown, Pennsylvania, specializing in regenerative medicine. The company focuses on developing innovative therapies to treat severe conditions such as Epidermolysis bullosa (EB). Through targeted research and funding, it works to advance clinical solutions for patients with rare genetic skin diseases.
Subscribe to see Eliksa Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Eliksa Therapeutics at a glance
Eliksa Therapeutics is a biotechnology company headquartered in United States. Its most recent funding round, Seed, closed in October 2025. Xcout tracks 1 named person at Eliksa Therapeutics, including Armen Karamanian (Chief Executive Officer).
Eliksa Therapeutics leadership
- Armen KaramanianChief Executive Officer
Eliksa Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | Undisclosed | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Eliksa Therapeutics competitors
A few of Eliksa Therapeutics's closest competitors — see the full list of competitors and alternatives →
ReadOn Therapeutics is a non-profit biotechnology organization focused on developing novel readthrough therapeutics for Epidermolysis Bullosa (EB). Operating with a presence in locations such as Munich, Germany, the organization partners with research entities like DEBRA Research to accelerate treatments for rare genetic disorders. Its scientific focus lies in advancing translational research to meet significant unmet medical needs.
Rinascera Therapeutics, Inc. is a clinical-stage biotechnology company located in Boston, Massachusetts, dedicated to transforming the treatment of rare genetic skin diseases.
Nova Anchora is a San Francisco-based biopharmaceutical company founded in 2021 that develops advanced topical protein therapies for rare skin diseases. The company's lead product in development, NvA-011, is a recombinant version of collagen VII designed as a topical gel for the treatment of dystrophic epidermolysis bullosa.
Kamal Therapeutics, Inc. is a pharmaceutical holding company located in Hingham, Massachusetts, focused on developing treatments such as intravenous recombinant human decorin for dystrophic epidermolysis bullosa.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Palvella Therapeutics is a biotechnology company headquartered in Wayne, Pennsylvania, that specializes in developing and commercializing medicines for patients with rare dermatological diseases. The publicly traded company operates with corporate offices and an active team dedicated to clinical and commercial development.
Get Eliksa Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Eliksa Therapeutics in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access